首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   563篇
  免费   12篇
  国内免费   3篇
儿科学   24篇
基础医学   38篇
口腔科学   1篇
临床医学   24篇
内科学   261篇
皮肤病学   11篇
神经病学   5篇
特种医学   2篇
外科学   31篇
综合类   44篇
预防医学   18篇
眼科学   1篇
药学   38篇
中国医学   73篇
肿瘤学   7篇
  2023年   1篇
  2022年   5篇
  2021年   15篇
  2020年   13篇
  2019年   71篇
  2018年   62篇
  2017年   49篇
  2016年   13篇
  2015年   13篇
  2014年   67篇
  2013年   40篇
  2012年   30篇
  2011年   27篇
  2010年   22篇
  2009年   21篇
  2008年   18篇
  2007年   26篇
  2006年   18篇
  2005年   14篇
  2004年   13篇
  2003年   13篇
  2002年   8篇
  2001年   3篇
  2000年   5篇
  1999年   3篇
  1998年   1篇
  1997年   1篇
  1989年   1篇
  1986年   1篇
  1985年   3篇
  1981年   1篇
排序方式: 共有578条查询结果,搜索用时 31 毫秒
1.
Background/purposeColectomy with ileal pouch-anal anastomosis (IPAA) is the standard of care for patients with familial adenomatous polyposis (FAP) and refractory ulcerative colitis (UC). The rates of postoperative complications are not well established in children. The objective of this systematic review is to establish benchmark data for morbidity after pediatric IPAA.MethodsPubMed, Embase, and The Cochrane Library were searched for studies of colectomy with IPAA in patients ≤ 21 years old. UC studies were limited to the anti-tumor necrosis factor-α agents era (1998–present). All postoperative complications were extracted.ResultsThirteen studies met the inclusion criteria (763 patients). Compared to patients with FAP, UC patients had a higher prevalence of pouch loss (10.6% vs. 1.5%). Other major complications such as anastomotic leak, abscess, and fistula were uncommon (mean prevalence 4.9%, 4.2%, and 5.0%, respectively, for patients with UC; 8.7%, 4.2%, and 4.3% for FAP). The most frequent complication was pouchitis (36.4% of UC patients).ConclusionsDevastating complications from colectomy and IPAA are rare, but patients with UC have poorer outcomes than those with FAP. Much of the morbidity may therefore stem from patient or disease factors. Multicenter, prospective studies are needed to identify modifiable risks in patients with UC undergoing IPAA.Level of evidencePrognostic, level II.  相似文献   
2.
While restorative proctocolectomy and ileal pouch-anal anastomosis significantly improves patients’ quality of life, the reconstructive surgery is often associated with various structural, inflammatory, and functional disorders. Those disorders have been traditionally managed with surgery. However, the past two decades have witnessed a growing role of endoscopic management of strictures, prolapse, anastomotic leaks, sinuses, fistulae, and polyps. The main advantages of endoscopic therapy are its less invasiveness in nature and better tolerance over surgery. Endoscopic sinusotomy is at least as effective as surgical pouch redo for a majority of pouch presacral sinuses, while carrying a lower risk for procedure-associated complications.  相似文献   
3.

Purpose

To determine the association of micropapillary urothelial carcinoma (MUC) variant histology with bladder cancer outcomes after radical cystectomy.

Materials and Methods

Information on MUC patients treated with radical cystectomy was obtained from five academic centers. Data on 1,497 patients were assembled in a relational database. Tumor histology was categorized as urothelial carcinoma without any histological variants (UC; n?=?1,346) or MUC (n?=?151). Univariable and multivariable models were used to analyze associations with recurrence-free (RFS) and overall (OS) survival.

Results

Median follow-up was 10.0 and 7.8 years for the UC and MUC groups, respectively. No significant differences were noted between UC and MUC groups with regard to age, gender, clinical disease stage, and administration of neoadjuvant and adjuvant chemotherapy (all, P ≥ 0.10). When compared with UC, presence of MUC was associated with higher pathologic stage (organ-confined, 60% vs. 27%; extravesical, 18% vs. 23%; node-positive, 22% vs. 50%; P < 0.01) and lymphovascular invasion (29% vs. 58%; P < 0.01) at cystectomy. In comparison with UC, MUC patients had poorer 5-year RFS (70% vs. 44%; P < 0.01) and OS (61% vs. 38%; P < 0.01). However, on multivariable analysis, tumor histology was not independently associated with the risks of recurrence (P?=?0.27) or mortality (P?=?0.12).

Conclusions

This multi-institutional analysis demonstrated that the presence of MUC was associated with locally advanced disease at radical cystectomy. However, clinical outcomes were comparable to those with pure UC after controlling for standard clinicopathologic predictors.  相似文献   
4.
陈思阳  邵强  张玉海 《北京医学》2006,28(9):534-536
目的 探讨直肠指检(DRE)、导尿术(UC)等相关因素对前列腺特异性抗原(PSA)检测结果的影响.方法 将60例健康者分为DRE组和UC组,每组30例.采用对比分析的方法分别观察DRE和UC前后血清PAS检测值的变化情况.结果 DRE前PSA(FPSA)和后PSA(TPSA)平均值为(1.05±0.10、2.82±0.97)ng/ml,DRE后第1、3、7天分别为(1.07±0.15、3.50±1.95)、(1.03±0.06、2.97±1.66)、(1.02±0.07、3.25±1.71)ng/ml;DRE组FPSA无显著升高,TPSA有所升高,于24h达最大值,其次为第7、3天.经统计学分析,DRE前后各组间PSA值均无显著性差异(P>0.05).UC的FPSA和TPSA平均值为(1.00±0.02、2.01±0.50)ng/m1,UC后第1、3、7天分别为(1.15±0.82、2.37±1.96)、(1.02±0.07、2.16±0.52)、(1.02±0.09、2.09±0.60)ng/ml;UC组FPSA术后24h有所升高,TPSA术后24h达最高值,之后逐渐降低,经统计学分析,UC前后各组间PSA值均无显著性差异(P>0.05).结论 正常血清PSA检测结果不受DRE和UC等因素的影响.  相似文献   
5.
目的:通过动物实验证实泄浊解毒方对溃疡性结肠炎(UC)大鼠治疗有效,并探讨其可能作用机制。方法:将40只实验大鼠随机分为空白对照组、模型对照组、柳氮磺吡啶组、中药高、低剂量组5组,除空白组外,其余4组均采用TNBS/乙醇联合造模法制造UC模型。分组灌胃治疗14 d后,分别检测大鼠血清IL-1β、IL-10、结肠黏膜CD14含量。结果:模型组较空白组IL-1β、CD14表达明显升高,IL-10表达明显下降,差异有显著性(P0.05);中药高、低剂量组、柳氮磺吡啶组较模型组IL-1β、CD14表达明显下降,IL-10表达明显升高,差异有显著性(P0.05);中药高剂量组较柳氮磺吡啶组、中药低剂量组IL-1β、CD14表达明显下降,IL-10表达明显升高,差异有显著性(P0.05)。结论:泄浊解毒方干预UC大鼠可降低血清IL-1β、升高血清IL-10、下调结肠黏膜CD14表达,这可能是其作用机制之一。  相似文献   
6.
安阿玥教授认为先天禀赋异常为溃疡性结肠炎(ulcerative colitis,UC)发生的重要前提,忧、思、郁、怒等不良情志刺激为其诱因,嗜食生冷、肥甘厚味、饮食不洁致湿热疫毒之邪内侵肠道为发病最直接原因,三者常相兼为患。安阿玥教授诊断用药强调中西医并重,二者互补短长,治疗用药方面,UC初起或急性期辨证为湿热交阻、气血壅滞证,主张以清热化湿,行气和血为主;病程日久辨证为寒热错杂、脾虚湿困证,以调补脾胃为主,辅以清热化湿,寒温并用、补泻兼施,寒温并用以和其阴阳,辛苦并进以调其升降,补泻兼施以顾其虚实;起病迅速病情危重的患者局部应用康复新液灌肠治疗。  相似文献   
7.
目的:观察健脾疏肝汤结合物理疗法治疗溃疡性结肠炎的临床疗效。方法:选取2014年1—12月本院治疗的溃疡性结肠炎患者88例,随机分为观察组和治疗组,每组44例。对照组给予健脾疏肝汤治疗,观察组在对照组治疗的基础上给予物理疗法治疗。结果:观察组腹痛评分、便血评分、腹泻评分、肠镜下结肠黏膜病变评分均优于对照组(P0.05);观察组有效率97.73%,对照组有效率84.09%,观察组优于对照组(P0.05)。结论:健脾疏肝汤结合物理疗法治疗溃疡性结肠炎疗效显著。  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号